Paradox Immunotherapeutics is a preclinical-stage biotech using a lead identification and validation platform to develop antibodies that selectively target misfolded proteins while sparing healthy proteins. The company is advancing therapeutic programs for immunoglobulin light chain amyloidosis (AL amyloidosis) and leukocyte chemotactic factor 2 amyloidosis (LECT2). Paradox says the new funding will accelerate its pipeline through significant milestones across multiple indications. Management highlights include Co-Founder and CEO Dr. Natalie Galant; SymBiosis Operating Advisor Sandy Zweifach recently joined Paradox as an independent director and Executive Chairman. The team notes prior success with a founding member’s previous antibody candidate that resulted in a $1.2B acquisition in 2021. Paradox has received multiple recognitions, including finalist status at J.P. Morgan's Life Sciences Innovation Summit and awards from BIO, the Termeer Foundation, DC Health Innovation, and Springboard Enterprises.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2025